Jiksak is a recipient of the first round of support from the Japan Patent Office’s IP Acceleration Program for Startups (IPAS)
Jiksak Bioengineering secures 170 million JPY from ANRI, OHARA Pharma, Essential Pharma, and MediFuture to commercialize the Nerve Organoid Chip and f
The report entitled “Generation of a Motor Nerve Organoid with Human Stem Cell-Derived Neurons” was published in Stem Cell Reports.
Jiksak presented a technical poster introducing its technology at the International Society for Stem Cell Research's annual conference, ISSCR 2017 in
Jiksak Bioengineering, Inc. established in Hongo, Tokyo, with an aim to develop therapies for ALS.